Inhalation Solution News Today

United Therapeutics Corporation announced today the commencement of litigation with the United States Food and Drug Administration . In the litigation, United Therapeutics alleges that the FDA...

Up to 60,000 patients in the United States may have PPF, with only one approved therapy available ...

Presentation Operator MessageOperator Good morning, and welcome to the United Therapeutics Corporation Second Quarter 2023 Earnings Webcast. My name is Danielle, and I will be your conference operator...

United Therapeutics Corporation , a public benefit corporation, announced today that the United States Court of Appeals for the Federal Circuit affirmed the district court decision in the patent...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States Court of Appeals for the Federal Circuit affirmed the district court decision in the patent litigation United Therapeutics brought a...

Results from the EXPEDITE study of Remodulin® induction prior to Orenitram® therapy to be presented at ATS Baseline patient data from the TETON studies of Tyvaso® Inhalation Solution in... | April 18, 2023

Lupin Limited today announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, to market a generic equivalent of Perforomist® Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P.

To expand Lupin's portfolio of inhalation products in the US

Lupin has announced signing of an agreement to acquire all rights to two inhalation medicines, Brovana® Inhalation Solution and Xopenex HFA® Inhalation Aerosol, from Sunovion Pharmaceuticals Inc. for a purchase price of $75 million.

The acquisition of said brands will expand Lupin’s portfolio of Inhalation products.